| Literature DB >> 22158684 |
Ludmila G de Oliveira1, Meiriane M Silva, Flávia C S de Paula, Elene C Pereira-Maia, Cláudio L Donnici, Carlos A de Simone, Frédéric Frézard, Eufrânio N da Silva, Cynthia Demicheli.
Abstract
Antimony(V) and bismuth(V) complexes of lapachol have been synthesized by the reaction of Ph₃SbCl₂ or Ph₃BiCl₂ with lapachol (Lp) and characterized by several physicochemical techniques such as IR, and NMR spectroscopy and X-ray crystallography. The compounds contain six-coordinated antimony and bismuth atoms. The antimony(V) complex is a monomeric derivative, (Lp)(Ph₃Sb)OH, and the bismuth(V) complex is a dinuclear compound bridged by an oxygen atom, (Lp)₂(Ph₃Bi)₂O. Both compounds inhibited the growth of a chronic myelogenous leukemia cell line and the complex of Bi(V) was about five times more active than free lapachol. This work provides a rare example of an organo-Bi(V) complex showing significant cytotoxic activity.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22158684 PMCID: PMC6264574 DOI: 10.3390/molecules161210314
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of lapachol (1) and lapachone derivatives.
1H- and 13C-NMR data of lapachol (Lp, 1) and (Lp)(Ph3Sb)OH (2) and (Lp)2(Ph3Bi)2O (3).
| Compound | Lp | (2) | (3) | Lp | (2) | (3) | |
|---|---|---|---|---|---|---|---|
| Solvent | CDCl3 | CDCl3 | CDCl3 | CDCl3 | CDCl3 | CDCl3 | |
| Number | |||||||
| 184.5 | 182.6 | 183.3 | |||||
| 152.7 | 158.1 | 156.0 | |||||
| 123.5 | 126.0 | 122.1 | |||||
| 181.7 | 184.9 | 185.5 | |||||
| 126.0 | 126.1 | 125.7 | 8.1 ( | 8.0 ( | 8.2 ( | ||
| 132.8 | 134.3 | 131.5 | 7.7 ( | 7.6 ( | 7.7 ( | ||
| 134.8 | 133.4 | 134.0 | 7.7 ( | 7.5 ( | 8.0 ( | ||
| 126.7 | 126.3 | 125.9 | 8.1 ( | 8.1 ( | 8.5 ( | ||
| 129.4 | 132.0 | 130.2 | |||||
| 132.9 | 133.4 | 133.6 | |||||
| 22.6 | 23.2 | 23.2 | 3.3 ( | 3.3 ( | 3.4 ( | ||
| 119.6 | 121.3 | 121.9 | 5.2 ( | 5.1 ( | 5.1 ( | ||
| 133.8 | 132.8 | 133.2 | |||||
| 25.7 | 25.6 | 25.7 | 1.7 | 1.6 | 1.6 | ||
| 17.8 | 17.7 | 17.8 | 1.6 s | 1.5 | 1.7 | ||
δ, chemical shifts in parts per million (ppm); J, coupling constants in Hertz.
Figure 2An ORTEP-3 projection of compound 2 showing the atom-numbering and displacement ellipsoids at the 30% probability level.
Figure 3An ORTEP-3 projection of compound 3 showing the atom-numbering and displacement ellipsoids at the 30% probability level.
Crystal data and structure refinement.
| Empirical formula | C66H58Bi2O7 | C33H28SbO4 | ||||
| Formula weight | 1381.08 | 610.30 | ||||
| Temperature | 295 (2) K | 295 (2) K | ||||
| Wavelength | 0.71073 Å | 0.71073 Ă | ||||
| Crystal system, space group | Monoclinic, C2/c | Monoclinic, P21/c | ||||
| Unit cell dimensions | a = 27.8310(5) Å | a = 14.9030(2) Å | ||||
| b = 15.6580(3) Å | β = 100.58(1)° | b = 8.9130(3) Å | β = 99.09(1)° | |||
| c = 27.1660(5) Å | c = 21.8200(3) Å | |||||
| Volume | 11637.2(4) Å3 | 2861.9(6) Å3 | ||||
| Z, Calculated density | 4, 1.58 Mg/m3 | 4, 1.42 Mg/m3 | ||||
| Absorption coefficient | 2.406 mm−1 | 0.99 mm−1 | ||||
| F(000) | 5408 | 1236 | ||||
| Crystal size | 0.42 × 0.31 × 0.29 mm | 0.32 × 0.27 × 0.22 mm | ||||
| Theta range for data collection | 2.6 to 27.53° | 2.6 to 27.4° | ||||
| Limiting indices | −36 ≤ h ≤ 36, −20 ≤ k ≤ 20, −35 ≤ l ≤ 35 | −19 ≤ h ≤ 19, −11 ≤ k ≤ 11, −27 ≤ l ≤28 | ||||
| Reflections collected/unique | 68287/13271 [Rint = 0.052] | 42238/6275 [Rint = 0.102] | ||||
| Completeness to theta = 27.52 | 98.8% | 98.8% | ||||
| Refinement method | Full-matrix least-squares | Full-matrix least-squares | ||||
| Data/restraints/parameters | 10165/0/676 | 4902/0/344 | ||||
| Goodness-of-fit on F2 | 1.242 | 1.027 | ||||
| Final R indices [I > 2σ(I) ] | R1 = 0.087, wR2 = 0.122 | R1 = 0.080, wR2 = 0.098 | ||||
| R índices (all data) | R1 = 0.232, wR2 = 0.289 | R1 = 0.245, wR2 = 0.266 | ||||
| Largest diff. peak and hole | 1.401 and −2.035 e.Å-3 | 1.935 and −0.965 e.Å−3 | ||||
Growth inhibition of K562 cells by lapachol, Ph3BiCl2, Ph3SbCl2, and their complexes.
| Lp | Ph3BiCl2 | Ph3SbCl2 | (Lp)2(Ph3Bi)2O | (Lp)(Ph3Sb)OH | |
|---|---|---|---|---|---|
| a IC50 (μM) | 9.2 ± 0.9 | 30.1 ± 0.1 | 17.6 ± 1.6 | 1.8 ± 0.3 | 36.4 ± 1.8 |
a IC50 is the concentration required to inhibit 50% of K562 cell growth (mean ± SD).